Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects ...

Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome.

An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited ...

Poorly controlled hypertension is a common problem worldwide, particularly in low-resource settings. We conducted an ...

Hosted by Arjun (Raj) Manrai, Ph.D. and Andrew Beam, Ph.D., NEJM AI Grand Rounds features informal conversations with a variety of unique experts exploring the deep issues at the intersection of ...

China has recently emerged as an important player in new drug development — a field traditionally dominated by the United States and Europe. This shift has implications for global access to new ...

A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR ...

Surgery is the main treatment for early-stage non–small-cell lung cancer (NSCLC), even though recurrence remains common. 1 Neoadjuvant chemotherapy has offered a modest survival benefit, 2 with few ...

In patients with STEMI with cardiogenic shock, early mechanical support with a microaxial pump reduced the risk of death at 180 days, with the survival benefit persisting up to 10 years despite dev ...

Explore this issue of The New England Journal of Medicine (Vol. 393 No. 8).